Акции Cochlear выросли на 2,32% на фоне ожиданий роста прибыли от новой системы Nucleus Nexa

Cochlear shares climbed 2.32% today to A$127.86, touching a session high of A$128.14, and extending a month long rally that has seen holders recapture 24.57% on the period. The shift in sentiment will be well received by beleaguered COH bulls who continue to nurse declines of 51% since the start of the year. The move reflects a continuation of momentum that has already lifted Cochlear’s share price 42% from its post-downgrade lows in April, when management slashed full-year 2026 underlying profit guidance by around 30% to A$290-330 million. That guidance cut triggered a sharp one-day reset, but investors have since rotated back into the name on the thesis that the Nucleus Nexa system – Cochlear’s first “smart” implant with upgradeable firmware – will drive a medium-term earnings repair through higher volumes, richer upgrade cycles and expanding services revenue into fiscal 2027. Today’s price action pushes the stock into technically overbought territory, with the 14-period RSI now at 71.34, a level that typically signals short-term momentum extension rather than a fresh fundamental catalyst. Volume of 341,740 shares suggests incremental buying rather than a surge in conviction. Volume today was moderate, not surging, which raises the question of whether conviction is building or whether this is simply the tail end of a technical rally? The Latest The backdrop for the recent rally is a broader rebound in Australian healthcare, with investors revisiting quality names after earlier underperformance. Cochlear has benefited from renewed interest in defensives and a tentative shift back into growth stocks with long-term structural tailwinds, even as the company navigates a difficult transition year. The April trading update laid bare the challenges: second-half sales growth guidance was trimmed to 2-6% in constant currency, with management citing softer implant demand in developed markets, Middle East conflict-related uncertainty, and a stronger Australian dollar that is expected to shave around A$25 million after-tax from second-half profit. The operational headwinds are tangible. Developed-market implant volumes remain constrained by hospital capacity, reduced referrals from the hearing-aid channel, and weak US consumer sentiment that is deterring adults and seniors from electing procedures. Western Europe is grappling with long waiting lists and industrial action, while the Middle East conflict has brought order cancellations, delivery delays and receivables risk of up to A$10 million. China’s reimbursement changes in special access zones are also reducing premium-tier sales. On top of that, lower production volumes are hitting gross margins by around A$20 million, and the company is booking A$18-25 million in cost-base reshaping expenses as it accelerates a restructuring program to create a more flexible, lower cost-to-serve platform. Top Australian Brokers - Pepperstone - Top Australian broker - Read our review - eToro - Invest in ASX and international shares - Read our review Yet management has reaffirmed confidence in the long-term growth trajectory, highlighting strong adoption and positive feedback for Nexa in developed markets and improving market share. The R&D pipeline includes drug-eluting electrodes and a totally implantable cochlear implant, with multiple clinical studies underway for regulatory approval. The Nexa rollout, including US FDA approval, is positioned as the foundation for a richer services upgrade cycle and a shift toward recurring revenue that could lift margins over time. That narrative has gained traction as investors look past the FY26 trough, and today’s strength suggests the market is continuing to price in that medium-term repair despite the unchanged near-term headwinds. The currency headwind remains a clear overhang. Cochlear’s guidance framework assumes AUD/USD around 0.71 and AUD/EUR 0.61, and current AUD strength is dilutive to reported earnings. The company has explicitly flagged the A$25 million after-tax impact to second-half profit at current FX levels, and any further AUD appreciation would compound the pressure. US consumer confidence, which Macquarie explicitly ties to implant demand in the Americas (around half of group revenue), has been at historic lows and is only slowly improving. US Medicare Advantage pressure and broader payer scrutiny remain a medium-term overhang. View From The Street Price Targets Consensus 12-month target price sits around A$125.39, implying the Street sees Cochlear as close to fully valued on current numbers. Recent broker notes from firms including Macquarie have generally landed at Neutral or Hold, with cautious language around FY26 earnings, US consumer sensitivity, Western Europe execution and foreign exchange, even as they acknowledge Cochlear’s dominant position and Nexa-driven upside longer term. Macquarie has linked implant demand to US consumer confidence and models FY26 profit around A$307 million, within but not above the new guidance range. The implication is clear: today’s price action is ahead of the Street rather than following it, with investors effectively paying upfront for a medium-term repair story that brokers are modelling more cautiously. Bull Case: - Nexa adoption accelerates, driving higher volumes and richer services upgrade revenue into FY27. - Cost-base restructuring delivers margin upside faster than guidance, offsetting near-term headwinds. - Healthcare sector rotation and defensive positioning support sustained premium valuation multiple. Bear Case: - Consensus target at A$125.39 offers minimal upside; stock is overbought and at resistance. - Developed-market implant demand remains soft; US consumer confidence and payer scrutiny weigh. - AUD strength and Middle East disruption continue to pressure earnings and receivables through FY26.